WHO pre­qual­i­fies Strides Sha­sun’s RAS prod­uct

BioSpectrum (Asia) - - Who News -

In­dian drug firm Strides Sha­sun has re­ceived pre­qual­i­fi­ca­tion from the World Health Or­ga­ni­za­tion (WHO) for its rec­tal arte­sunate prod­uct for the pre-re­fer­ral man­age­ment of se­vere malaria. The pre-qual­i­fi­ca­tion from the WHO for the 100mg rec­tal arte­sunate sup­pos­i­to­ries (RAS) has been achieved with sup­port from Medicines for Malaria Ven­ture (MMV) and fund­ing from Uni­taid. This pre-qual­i­fi­ca­tion en­ables coun­tries to pro­cure life-sav­ing RAS with donor fund­ing, thus en­sur­ing in­creased ac­cess to this po­ten­tially life-sav­ing in­ter­ven­tion. The com­pany will now lever­age its sig­nif­i­cant pres­ence in Africa to reg­is­ter and dis­trib­ute the prod­uct where needed on the con­ti­nent. To this end, dossiers have al­ready been sub­mit­ted in 25 of the coun­tries that could ben­e­fit most.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.